Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.8K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.8K
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

1.5K
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
1.5K
Esophageal Achalasia01:27

Esophageal Achalasia

45
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide...
45
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

1.1K
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.1K
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

1.1K
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
1.1K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

807
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
807

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Development and Validation of a Large Language Model Case Identification Strategy for Eosinophilic Esophagitis.

Gastro hep advances·2026
Same author

Interleukin-13 Promotes Accumulation of Esophageal Epithelial Mitochondria With Translational Implications for Eosinophilic Esophagitis.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Effect of Budesonide Oral Suspension on Time to First Dysphagia Symptom Response and Dysphagia Symptom Resolution Outcomes in Patients With Eosinophilic Esophagitis.

Journal of gastroenterology and hepatology·2026
Same author

American Society for Gastrointestinal Endoscopy consensus recommendations on the endoscopic management of eosinophilic esophagitis-part 2: disease assessment, monitoring, and pediatric considerations.

Gastrointestinal endoscopy·2026
Same author

Patient-Reported Outcome Scores Are Comparable in Multiregional Versus Uniregional Eosinophilic Esophagitis.

Gastro hep advances·2025

Related Experiment Video

Updated: May 4, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

13.1K

Update on ablation for Barrett's esophagus.

Gary W Falk1

  • 1Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, 9 Penn Tower, One Convention Avenue, Philadelphia, PA, 19104, USA, gary.falk@uphs.upenn.edu.

Current Gastroenterology Reports
|December 21, 2013
PubMed
Summary

Endoscopic ablation offers significant benefits for Barrett's esophagus patients with high-grade dysplasia and intramucosal carcinoma. While effective for low-grade dysplasia, recurrence and progression risk necessitates ongoing research into predictors of response and durability.

More Related Videos

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation
06:25

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

12.9K
Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

10.5K

Related Experiment Videos

Last Updated: May 4, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

13.1K
Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation
06:25

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

12.9K
Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

10.5K

Area of Science:

  • Gastroenterology
  • Endoscopic procedures
  • Barrett's esophagus management

Background:

  • Barrett's esophagus (BE) is a premalignant condition.
  • High-grade dysplasia (HGD) and intramucosal carcinoma (IMC) in BE are indications for treatment.
  • Endoscopic ablation has emerged as a key therapeutic modality.

Purpose of the Study:

  • To review the current evidence for endoscopic ablation in managing Barrett's esophagus.
  • To assess the efficacy and safety of endoscopic ablation across different BE grades.
  • To discuss the durability, recurrence, and progression of disease after ablation.

Main Methods:

  • Review of recent clinical studies and literature on endoscopic ablation for Barrett's esophagus.
  • Analysis of data regarding efficacy in high-grade dysplasia, intramucosal carcinoma, and low-grade dysplasia.
  • Evaluation of safety profiles and disease progression/recurrence rates.

Main Results:

  • Endoscopic ablation is highly effective for HGD and IMC in BE.
  • Evidence supports ablation for low-grade dysplasia (LGD) but not for nondysplastic BE.
  • Disease progression can occur during and after ablation; recurrence rates vary.

Conclusions:

  • Endoscopic ablation is a safe and effective treatment for HGD and IMC in BE.
  • Ablation shows promise for LGD, but careful patient selection is crucial.
  • Further research is needed to identify predictors of response and recurrence to optimize long-term outcomes.